Gastroenterology Market (By Type: Branded, Generics; By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies; By Application: Crohns Disease, Ulcerative Colitis, GERD, IBS, Others; By Route of Administration: Injectable, Oral & Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global gastroenterology market size was estimated at USD 34.53 billion in 2023 and it is expected to hit around USD 61.56 billion by 2033, poised to grow at a CAGR of 6% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Gastrointestinal disorders are gastrointestinal illnesses that affect the colon, small and large intestines, and the rectum. Irritable bowel syndrome, peptic ulcer diseases, and constipation make up most of the problems. These are all characterized by symptoms like discomfort, bloating, diarrhea, nausea, and vomiting. The term "gastrointestinal therapies" refers to a class of medications that includes the following: Prilosec, Aciphex, Afinitor, Akynzeo, and Akynzeo.
The primary reasons propelling market expansion include expanding geriatric population, geriatric occurrences, overcrowding in the hospital outpatient department (HOPD), and rising demand for ambulatory treatments to minimize irrational hospitalization costs.
The market will grow in size during the projected period as a result of factors such as an increase in chronic diseases, a growth in the older population, unhealthy lifestyles, and an increase in the number of surgeries in the world.
The U.S. gastroenterology market size was valued at USD 11.91 billion in 2023 and is expected to be worth around USD 20.97 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.
Technological advancements, an increase in gastrointestinal diseases, an increase in the number of geriatric and obese people, and an increase in research and development activities with the presence of major market players are some of the factors propelling market growth in the North American region.
Patients with co-morbid diseases, those who have impaired immune systems, and those who are malnourished and immunosuppressed have been shown to experience more severe COVID-19 infections. Crohn's disease and ulcerative colitis are both intestinal and extraintestinal manifestations of the chronic remitting and relapsing condition known as inflammatory bowel disease (IBD). Due to their frequent malnutrition and use of immunosuppressive drugs, people with inflammatory bowel disease (IBD) may be significantly more likely to get COVID-19 infection.
The rising incidence of gastrointestinal disorders brought on by unhealthful eating patterns, the expansion of clinical studies with reliable findings, rising healthcare costs, and the rise in the elderly population are the main drivers of the gastroenterology market. But it's anticipated that the market will not grow as quickly as it may due to drug side effects and strict regulatory rules for drug approval.
In the near future, the gastroenterology industry will experience significant demand due to rising demand for self-medication and regenerative medicines, as well as several patient support programs implemented in emerging nations. Hospital patient loads have increased as a result of an increase in surgical operations, particularly small inpatient surgeries such as minor joint repair, abdominal hernia repair, gall bladder removal, cataract surgery, and other treatments. One of the main forces fueling the market's expansion is the increasing number of patients.
Report Coverage | Details |
Market Size in 2023 | USD 34.53 Billion |
Market Size by 2033 | USD 61.56 Billion |
Growth Rate from 2024 to 2033 | CAGR of 6% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Type, By Distribution Channel, By Application and By Route of Administration |
Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Market Drivers
The growing size and quantity of investments made in the healthcare system by governments and commercial companies of different countries are one of the primary drivers fueling the market's growth. The rapid economic development and the rising expense of healthcare would give more developing nations better access to high-quality care. Governments from several countries are attempting to improve residents' access to high-quality medical care and increase payment choices.
Additionally, pharmaceutical and biotechnology businesses are focusing more on R&D to find and create new medications for treating gastrointestinal illnesses, expanding their product pipeline. Additionally, the global increase in drug development for gastrointestinal illnesses is anticipated to contribute to the growth.
Market Restraints
The market's expansion is constrained by the increase in healthcare costs. In addition, the market's expansion is constrained by the lack of access to medical services and treatments. Among inflammatory diseases, chronic gastritis is quite frequent. In many patients, the inflammatory stomach mucosa exhibits a tendency to atrophize over time (atrophic gastritis). Gastritis typically lasts a lifetime, and patients with autoimmune chronic corpus gastritis have very low chances of spontaneous recovery.
The Helicobacter pylori bacterium has been linked to gastritis. Gastric secretory processes, such as pepsin, gastric acid secretion, and gastrin, are hampered by inflammation and atrophy of the gastric mucosa. Therefore, it is anticipated that the gastroenterology field will suffer from the lack of effective and long-lasting treatments for gastrointestinal diseases.
Market Opportunities
The market will rise in the future as technologically sophisticated surgical techniques like minimally invasive operations become more commonplace, and as patients come to accept and become more aware of these procedures being provided in ambulatory facilities. This represents a significant prospective growth opportunity for the market during the anticipated term.
The market's simple access to medications to treat ulcerative colitis can be credited with the segment's expansion. The strong clinical urgency to stop the spread of ulcerative colitis is another factor contributing to the segment's expected rapid growth. Due to the poor prognosis and use of harmful foods, there is a great likelihood that the condition will return.
In Japan, there were over 180,000 people with ulcerative colitis, according to a study by Shinji Okabayashi et al. that was published in the Journal of the Anus, Rectum, and Colon in January 2020. Additionally, it has been noted that in newly industrialized areas of Latin America, ulcerative colitis (UC) incidence and prevalence are increasing.
The incidence and prevalence of ulcerative colitis (UC) in Latin America were 0.04 to 8.00/100,000 and 0.23 to 76.1/100,000, respectively, according to a study by Paulo Gustavo Kotze et al. that was published in Therapeutic Advances in Gastroenterology Journal in July 2020. As a result, studies and research indicate that the prevalence and incidence of Ulcerative Colitis are rising, which is driving demand for the market.
Growing R&D initiatives are also accelerating market expansion. There are over 245 current clinical studies for ulcerative colitis in various stages of development, according to the National Clinical Trials (NCT) registry as of May 2021. With the success of this research, ulcerative colitis patients might anticipate new, efficient treatments in the upcoming years.
The gastroenterology market is divided into branded and generic segments based on type. In terms of revenue, the branded segment led the gastroenterology market in 2023 owing to the good commercial performance of branded gastrointestinal products, the investigational pipeline's promising candidates combined with the high costs, and the market exclusivity. Additionally, it is estimated that the category will expand during the projected period due to the increasing regulatory approvals of branded pharmaceuticals.
The gastroenterology market is divided into hospital pharmacies, retail pharmacies, and online pharmacies according to the distribution channel. In 2023, the market for gastroenterology saw a significant revenue share for the online pharmacies industry. This is a result of rising online pharmacy trends, increased internet usage, and the numerous discounts provided by online pharma players. Additionally, the market sector is anticipated to develop during the anticipated period due to the rise in telemedicine adoption that occurred during the pandemic and continues to grow even after COVID-19.
The gastroenterology market is divided into categories based on application, including Crohn's disease, ulcerative colitis, GERD, IBS, and others. In terms of revenue share, the gastroenterology market's Crohn's disease sector led the way in 2023.
This is because there have been more cases of Crohn's disease (CD) over the past five decades, more novel drugs are being approved for CD, and there are more diagnostic options for the disease, such as imaging modalities or serological markers, which are expected to boost the market for CD during the forecasted period.
The gastroenterology market is segmented into oral, injectable, and other segments based on the route of administration. In the gastroenterology market in 2023, the injectables segment accounted for the largest revenue share. The elements driving the market's expansion include higher pricing, quick onset of action, better bioavailability, and a lower likelihood of first-pass metabolism in the case of injectable pharmaceuticals, as well as the higher acceptance rate of biological drugs.
Segments Covered in the Report
By Type
By Distribution Channel
By Application
By Route of Administration
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gastroenterology Market
5.1. COVID-19 Landscape: Gastroenterology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gastroenterology Market, By Type
8.1. Gastroenterology Market, by Type, 2023-2032
8.1.1. Branded
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Generics
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Gastroenterology Market, By Distribution Channel
9.1. Gastroenterology Market, by Distribution Channel, 2023-2032
9.1.1. Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Gastroenterology Market, By Application
10.1. Gastroenterology Market, by Application, 2023-2032
10.1.1. Crohn's Disease
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Ulcerative Colitis
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. GERD
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. IBS
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Gastroenterology Market, By Route of Administration
11.1. Gastroenterology Market, by Route of Administration, 2023-2032
11.1.1. Injectable
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Oral & Others
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Gastroenterology Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Route of Administration (2020-2032)
Chapter 13. Company Profiles
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Johnson & Johnson
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. AbbVie Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Salix Pharmaceuticals
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GlaxoSmithKline Plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ALLERGAN
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Takeda Pharmaceutical Company Limited
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. AstraZeneca
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Astellas Pharma US, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client